Evidence map›Paper›PMID 18990298›Full record

ReviewCurrent diabetes reports2008

Gene therapy for the treatment of diabetic neuropathy.

Marina Mata, Munmun Chattopadhyay, David J Fink

Open access · greenAbstract readReview
In one paragraph

Review in Current diabetes reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. HSV Recombinant Vectors for Gene Therapy.The open virology journal · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Marina MataDepartment of Neurology, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Munmun Chattopadhyay
David J Fink
University of Michigan–Ann Arbor · US

Funding

PRE-CLINICAL VECTOR PRODUCTIONP01DK044935 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLORIOSO, JOSEPH C · 1993 to 2010
$11.8M
GENE TRANSFER FOR PREVENTION OF DIABETIC NEUROPATHYR01NS038850 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FINK, DAVID J. · 1999 to 2012
$3.3M
NIDDK NIH HHS DK044935NIDDK NIH HHS P01 DK044935NINDS NIH HHS NS038850NINDS NIH HHS R01 NS038850
6 · The paper itself

Abstract

Neuropathy is a common, untreatable complication of type 1 and type 2 diabetes. In animal models peptide neurotrophic factors can be used to protect against the development of neuropathy, but the combination of short half-life and off-target effects of these potent pleiotropic peptides has limited translation to human therapy. Gene transfer is a promising strategy that may circumvent these limitations. In this article, we review the basic methods of gene transfer and the -preclinical data in rodent models that support the use of this approach in the treatment of diabetic neuropathy. The path to clinical applications and potential pitfalls in developing gene therapy for the treatment of diabetic neuropathy are considered.

Indexed as

Diabetic NeuropathiesGenetic TherapyHumans

Identifiers

PMID18990298
PMCPMC2730886
OpenAlexW2113430553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.